Valneva Shares Surge 11.83% to €2.68, Marking the Strongest Rebound in the SBF 120
Valneva, a vaccine-specialized laboratory, records the highest rebound in the SBF 120 on Monday midday, climbing to €2.68, while the broader index drops by 0.85% during the session. This marks a significant recovery after several weeks of continuous decline.
Valneva leaps by 11.83% to €2.68, leading the SBF 120 at midday, ahead of Nanobiotix (+10.46%) and Teleperformance (+5.13%). The stock has gained 16.09% over the week but still shows a decline of 35.6% over three months. This session partially reverses the sharp drop observed at the end of April and beginning of May, following the completion of an €84 million capital raise on April 30, which had weighed on the stock price. Today's rebound occurs without any specific news from the group during the session. This movement goes against the trend of the CAC 40, which is down 0.96% at 8,034.88 points, and the SBF 120, which has fallen by 0.85%. It is worth recalling that the stock also suffered from a downgrade by Goldman Sachs to 'sell' on April 22, adding to an already heavy bearish sequence.
Exiting the Low Zone, Resistance at €2.85
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The stock price has moved back above the MM20 at €2.46 (a +9.11% gap), but remains far from the MM50 at €3.32 and the MM200 at €3.87. Thus, the medium-term trend is still bearish, despite today's surge. The RSI at 36 has exited the oversold zone where it had been for several sessions. With the intraday rise, the stock approaches the upper Bollinger Band at €2.74, which is 90% of the amplitude, and heads towards the technical resistance identified at €2.85. Breaking through this threshold would open the way towards the MM50. On the calendar side, the laboratory will participate in the Bernstein European Small & Mid-Cap Conference on May 21, before two general meetings scheduled for June 1 and June 25. The first quarter 2026 results, initially expected on May 13, were already covered on May 5. The next identified stock market event is therefore the Bernstein conference on May 21.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.